Member Info for Moneymunch

Profit takers, all in the mix regardless and no doubt wished they'd held on to them soon enough. Multiple potential game changing material newsflow in the pipeline to take the sp to new highs and beyond!!! A very exciting period ahead for all invested. Gl :-)

Acuitas Therapeutics Announces Four Scientific

Presentations at the 2026 ASGCT Annual Meeting

Vancouver, B.C. -

Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, today announced it will present new research at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

The presentations will showcase Acuitas’ latest advancements in the biology and mechanisms of LNP delivery, ranging from raw material quality control to cell-specific targeting.

The ASGCT Annual Meeting will be held from May 11 – 15, 2026, in Boston. Acuitas' researchers will share insights into how the chemical properties of lipids and the biological responses of the host environment can be optimized to create more potent, safer, and highly targeted genetic medicines.

“Acuitas is dedicated to advancing LNP technology through robust scientific validation and expanding its role in next-generation vaccines and therapeutics," said Acuitas Chief Scientific Officer Ying Tam. “Our research at ASGCT reflects our belief that the most transformative RNAbased medicines are realized when we understand the complex biology and mechanisms of LNP delivery, facilitating our work alongside the global scientific community to accelerate life-changing treatments.”

Acuitas Therapeutics + Follow ٠٠٠ ACUITAS 15,744 followers 13h.

Targeted mRNA delivery to specific target cells is here

At #ASGCT2026 this May, hosted by American Society of Gene & Cell Therapy in Boston, we'll be sharing new research focused on the delivery science behind therapeutic success. From targeted in vivo CAR T generation to the impact of lipid adducts and immune stimulation, our presentations explore key factors that can shape the performance of RNA-LNP therapeutics

The data is now live! Explore our abstracts here: htTps://lnkd.in/gtURh4EW

#Biotech #GeneTherapy #CART #LNP #InVivo #PrecisionMedicine

Genflow Biosciences (LON:GENF) and the Breakthrough Promise of Gene Therapy in Childhood Blindness

A landmark case in paediatric genetic medicine is drawing attention to the transformative potential of gene therapy, highlighting how cutting-edge biotechnology could reshape the future of inherited diseases. For companies such as Genflow Biosciences (LON:GENF), which focuses on advancing therapies that address the biological mechanisms of aging and genetic dysfunction, developments like these underscore the growing relevance of genomic innovation in modern healthcare.

..........

Genflow Biosciences and the Genetics of Longevity

Genflow Biosciences (LON:GENF), a UK-based biotechnology company with research operations in Belgium, is part of a broader movement exploring how genetic interventions can enhance health outcomes. While its primary focus is on therapies targeting the aging process in humans and dogs, the company operates within the same scientific ecosystem that enables breakthroughs like gene therapy for inherited blindness.

By investigating genes associated with cellular repair, longevity, and metabolic resilience, Genflow Biosciences is contributing to a deeper understanding of how genetic pathways influence disease progression and recovery. This work aligns with the broader trend of precision medicine, where treatments are tailored to the genetic profile of individual patients.

Dr. Eric Leire, CEO of Genflow Biosciences, highlighted the significance of such advancements:

“Saffie’s story shows why innovation in genetic medicine matters. No child should grow up fearing the loss of their sight when gene therapy can offer real hope.”

Genflow Biosciences (LON:GENF) And The Breakthrough Promise Of Gene Therapy In Childhood Blindness htTps://share.google/7p4LEIJo1ODxHm2CT

As of April 2026, Genflow Biosciences (LSE:GENF) has entered into confidential disclosure agreements (CDAs) with multiple "Tier-1" global animal health companies to explore partnerships, licensing, or co-development of its proprietary SIRT6 gene therapy for aging dogs (GF-1004).

Following positive, durable, and safe interim results from its canine trials (SLAB study) released in February 2026, Genflow has widened these discussions to include a "broader group of counterparties" as interest grows in its longevity platform.

Key Developments in Potential Partnership

Active Negotiations: In early 2026, Genflow announced it was in active discussions with top-tier, established players in the animal health industry.

Data Validation: The interest is driven by preliminary results showing superior survival rates in treatment groups vs. controls, along with increased quality of life, muscle preservation, and reduced frailty in aged dogs.

Strategic Goal: Genflow is seeking to license its canine program, using a "non-dilutive" funding strategy where partners fund development in exchange for commercialization rights.

Market Anticipation: There is high, albeit unconfirmed, anticipation from investors of a potential "bidding war" or high-value licensing deal as the study concludes in early 2026.

The Technology (SIRT6 Dog Trial)

Target: The trial uses a unique SIRT6 variant (found in human centenarians) delivered via AAV vectors to enhance DNA repair and metabolic regulation in senior dogs (10+ years).

Milestones: The study demonstrated excellent safety and durability, with positive results sustained three months post-dosing.

Goal: To achieve conditional approval as early as 2026, potentially creating a "first-in-class" longevity product for the companion animal market.

While the names of the Tier-1 animal health companies remain under strict confidentiality, the company has stated they are "leading participants" in the sector.

Let the the bidding war begin!!! Gla holders;-)

Expansion of Confidentiality Agreements

GENFLOW BIOSCIENCES PLC

Released 07:00:07 28 April 2026

RNS Number : 1116C

Genflow Biosciences PLC

28 April

Genflow Biosciences Plc

Expansion of Confidentiality Agreements with Tier-1 Animal Health Companies

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces the expansion of its engagement with participants in the global animal health sector.

Following the positive preliminary interim results reported in an RNS on February 12, 2026 and the initial execution of confidentiality agreements, the Company has entered into additional confidential agreements with Tier-1 global animal health companies in connection with the ongoing review of data from its canine SIRT6 cent gene therapy programme. These agreements, together with previous confidentiality agreements, reflect a broadening base of third-party evaluation of the Company's data and underlying technology.

These interactions support an ongoing evaluation process and remain exploratory in nature. The Company will provide further updates as appropriate.

Dr Eric Leire, Chief Executive Officer of Genflow Biosciences said: "We are encouraged by continued and new discussions with leading participants in the animal health sector. Our previously reported positive preliminary findings are now being evaluated by a broader group of counterparties under confidentiality agreements as part of an ongoing review of our canine programme. Our focus remains on advancing the programme and generating further data to support future development."

0.0533 = 3.9p

33.25% up on OTC. Gla :-)

GENFF

Genflow Biosciences Plc

Ordinary Shares

0.0533

0.0133

33.25%

0.03 / 0.0533 (20000 x 10000)

Real-Time Best Bid & Ask: 01:30pm 04/27/2026

Delayed (15 Min) Trade Data: 12:59pm 04/27/2026

Genflow's Final Results are due 30th April, and so would be very nice if we had an update or two prior to their release. Gla holders:-)

Every chance pickedpeck, and continued UPward momentum in anticipation, 3p plus and more tomorrow, regardless. Gl ;-)

No doubt due-diligence in progress pickedpeck, by one or both of the Animal Healthcare companies who have signed Confidential Disclosure Agreements, and given Eric's reference to Merck, who had suggested Genflow should look into Sirt6's Gene Therapy potential for Dogs, every chance Merck Animal Health could be in the frame. Confirmation of a commercial deal will be transformational for all concerned. Excitement building as game changing news could be very close!!! Gl ;-)

Biopharma Research - MSD Animal Health https://share.google/jTFpZaKa84xwT4z5e

Biopharma Research

Healthy animals are the foundation of a healthy world. As threats to animal health evolve, so do our solutions. At MSD Animal health, we are committed to continuous innovation in biopharma research—not just to treat illness today, but to build a healthier, more resilient future for animals and the people who depend on them.

We are focused on advancing veterinary medicine in key therapeutic areas from combating parasites and infections to improving animal health and performance.

Development

We aim to be the first when it comes to discovering and developing first- and best-in-class veterinary medicines and vaccines. We have a proven track record in small molecules, vaccine technologies and biotechnologies, such as monoclonal antibodies.

Our robust portfolio of veterinary medicines and vaccines reflects our unwavering commitment to advancing veterinary medicine.

Innovation

We have some ambitious goals when it comes to advancing animal health and we know it will take strategic partnerships to achieve them. That’s why we invest in co-innovation partnerships with pharmaceutical, crop science companies and academic institutions, along with internal discovery efforts.

We also collaborate closely with our colleagues at MSD Human Health to share best practices and leverage the power of our combined research effort.

They want your shares!!! Hold on tight and enjoy the ride!!! :-)))

Maybe the last chance to get in sub 3p before the next RNS lands, multiple potential material newsflow in the pipeline. Gla ;-)

All bodes well, and as pickedpeck highlighted, "it was people from Merck, who first suggested Genflow should look into Sirt6's potential for Dog healthspan and longevity ", and so every chance they're one of the Animal Healthcare companies who have signed Confidential Disclosure Agreements, and hopefully not too long before we find out. Any commercial deal would send the sp into orbit!!!

There's multiple potential material newsflow in the pipeline, with Key Patent Grant , "extremely close", and Methylation Clock Data from the Dog Study, expected soon, as well as progress updates on the other programs, and with an upturn in buying volume as market and investor interest inceases on Genflow's transformational UPside potential and prospects , this could be the last chance to get in at sub 3p, before the next RNS is delivered. Gla holders, Exciting times, Genflow are in transition from small cap to mid cap, and it's in progress, now!!! :-)

A $50m upfront payment with milestones and royalties should do it!!!??? GL ;-)

More than possible Porter, although the company would look very different from it does now i reckon, new Major US investors along with their new BoD's , Gad could still play a roll given his US background in Global Biotech and US capital markets etc, and Eric would probably move over into a more scientific roll and a new CEO along with a raft of other execs would be appointed to take Genflow to the next level....Exciting times ahead regardless. Gl :-)

To list on the Nasdaq Stock Market, companies must satisfy a minimum bid price of at least $4 per share at the time of initial listing. In some cases, a closing price of $3 or $2 per share may be acceptable if the company meets higher requirements for net tangible assets, operating history, or market value.

Bring it on Porter, either or, looks like we're on to a winner, potentially the Stellar share of 2026 and beyond!!! Gl ;-)

Ps a Nasdaq listing would be transformational and propel Genflow's value to exponential highs, and no doubt i inevitable by the time the Animal Healthcare commercial deal is confirmed. Very exciting times for all invested!!!

Pps I bought into Summit Therapeutics a few years back at 2.5p with a m/c of a few million, and accumulated around 1m shares up to 8p, they did hit 19p as far as I remember but the sp tanked on negative trial data on Duchenne Muscular Dystrophy , they did have a other promising target on C-Diffcile, but i decided to sell up and invest elsewhere. A year or so later they listed on Nasdaq, and last year the sp hit $38 on first in class data for Lung Cancer and today their sp is c$25 which equates to a market cap of $19 billion, and alas i didn't tuck a few away, and so imagine Genflow's potential on Sirt6 extending Dogs healthspan , first in class for Glaucoma, Mash Sarcopenia etc...mind boggling numbers!!! Gl ;-)

Nice one pickedpeck, very exciting as market and investor interest gathers pace on Genflow's cutting edge Sirt6 Gene Therapy Platform's potential and prospects, Major Pharma must be forming an orderly queue. Game changing news at anytime, and shouldn't be too long before the sp heads to new highs in anticipation. Gl :-)